Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical cancer. 1990

H Mori, and T Hanabayashi, and Y Yamada, and T Tamaya
Department of Obsetrics and Gynecology, Gifu University School of Medicine, Japan.

The interferon-gamma (IFN-gamma) productivity of peripheral blood mononuclear cells (PBMCs) was examined in 30 patients with uterine cervical cancer. The patients under 50 years of age had decreased IFN-gamma production compared with the age-matched controls. The IFN-gamma productivity in the patients over 50 years of age was decreased as well as in the age-matched controls. The proportion of monocytes in PBMCs did not correlate with the IFN-gamma productivity. The prostaglandin E2 (PGE2) productivity of PBMCs increased with the progress of cancer. PGE2 inhibited the IFN-gamma production by PBMCs, and the sensitivity of PBMCs to PGE2 was increased in the patients and controls over 60 years of age. The addition of indomethacin resulted in an increase in IFN-gamma production by PBMCs. These results suggest that the increased production of PGE2 and/or increased sensitivity to PGE2 are responsible for the decreased IFN-gamma production in patients with cervical cancer.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Mori, and T Hanabayashi, and Y Yamada, and T Tamaya
September 1984, Clinical and experimental immunology,
H Mori, and T Hanabayashi, and Y Yamada, and T Tamaya
January 1987, Hepatology (Baltimore, Md.),
H Mori, and T Hanabayashi, and Y Yamada, and T Tamaya
December 1987, Regulatory peptides,
H Mori, and T Hanabayashi, and Y Yamada, and T Tamaya
September 1987, The Journal of clinical investigation,
H Mori, and T Hanabayashi, and Y Yamada, and T Tamaya
April 1990, Journal of interferon research,
H Mori, and T Hanabayashi, and Y Yamada, and T Tamaya
October 1993, Gastroenterologia Japonica,
H Mori, and T Hanabayashi, and Y Yamada, and T Tamaya
March 1984, Nagoya journal of medical science,
H Mori, and T Hanabayashi, and Y Yamada, and T Tamaya
July 1984, Cancer research,
H Mori, and T Hanabayashi, and Y Yamada, and T Tamaya
December 2000, Journal of periodontal research,
Copied contents to your clipboard!